Open Aperture
Apertura Gene Therapy has engineered TfR1 CapX, a central nervous system (CNS)-targeting AAV capsid that binds to the human Transferrin Receptor 1 (hTfR1). This engineered affinity facilitates transport across the blood-brain-barrier, allowing for broad CNS distribution.
The Open Aperture MTA (Material Transfer Agreement) program provides qualified academic researchers with no-cost access to TfR1 CapX for non-commercial research. Our aim is simple: to reduce time and friction so that promising ideas can be evaluated quickly and rigorously. Learn more about Apertura’s novel TfR1 CapX capsid here.
- No cost capsid access for eligible academic laboratories
- A streamlined online application
- Practical guidance on CMC and preclinical development from Apertura
- Introductions to CMC and CRO vendors experienced with TfR1 CapX therapeutics
Principal Investigators (PIs) and research teams at accredited academic institutions pursuing non-commercial research.
If you do not have an academic affiliation (e.g., for-profit, not-for-profit, or foundation), we are happy to discuss alternative access pathways. Please contact us at info@aperturagtx.com.
- Learn more about the program by following the link below.
- Apply by filling in a short intake form.
- We review your application for eligibility and completeness. If your institution lacks an MTA with Apertura Gene Therapy, we send your Technology Transfer Office a CDA plus MTA packet for signature; if an MTA with your institution already exists, Apertura Gene Therapy can add your laboratory as an authorized group in the existing MTA.
- After execution of the MTA, Apertura will provide a documentation package that includes preclinical and CMC resources.
